A Phase 1 interventional study of E-CEL UVEC cells (AB-207) in Chronic Anal Fissure, sponsored by Weill Medical College of Cornell University. Recruiting at 1 site in United States. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-04-08.
Sponsored by Weill Medical College of Cornell University · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
This clinical trial is being conducted by investigators who are colorectal surgeons. Eligible study participants will receive the experimental treatment E-CEL UVEC cells by direct injection into the anal fissure. The study is being conducted to determine if E-CEL UVEC cell injections will be safe and would have any effects on healing of the anal fissure.
This Phase 1b trial is conducted to evaluate the initial safety and efficacy of local (percutaneous) injections of E-CEL UVEC cells, genetically-engineered (pro-survival gene, E4ORF1+), human umbilical vein endothelial cells, as an experimental treatment of patients with chronic anal fissure (CAF) who have failed medical therapy (i.e., topical vasodilators ± botulinum injection). The study is a non-randomized, open-label, single arm study, meaning every study participant will receive some dose of the experimental study drug (no placebo). Consented, eligible participants will receive percutaneous injections of E-CEL UVEC cell product along the sides of the fissure; the treatments are spaced 3 to 4 weeks apart. Initial safety and efficacy parameters will be observed over a 6-month period, followed by a long-term follow-up consisting of annual questionnaire provided by electronic means.
This research study is being done because, in animal studies, E-CEL UVEC cells have been shown to aid in restoring or accelerating the normal healing in various tissues. This study will test if it is safe to use E-CEL UVEC cell therapy and if they it would aid in restoring or improve healing of CAF that was not responding to medical therapy. Improvement of CAF would be assessed in a standard, clinical manner (using brief digital palpation by the doctor), a method acceptable to the FDA, versus the original method (detailed quantitative photo-documentation). This study is being led by Dr. Kelly Garrett, Associate Professor of Surgery, and conducted by surgeons in the Colon and Rectal Surgery Division of Weill Cornell Medical College.
84 studies on the registry are indexed under Fissure in Ano; 16 are open to participants now.
This study's planned enrollment of 20 is below the median of 99 across 65 interventional studies indexed under Fissure in Ano.
Browse Fissure in Ano studies →Weill Medical College of Cornell University is the lead sponsor of 893 studies on the registry; 165 are open to participants now.
Of its 124 completed or terminated interventional studies of FDA-regulated products, 95 (77%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Vital signs upon screening:
Exclusion Criteria:
Hepatic impairment defined by both of the following laboratory ranges:
(a) total ≥ 1.5 x ULN unless benign congenital hyperbilirubinemia; and (b) (AST) and alanine aminotransferase (ALT) ≥ 2.5 x ULN
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Local percutaneous injection of E-CEL UVEC cells around the anal fissure
Biological: E-CEL UVEC cells (AB-207)
Allogeneic (consented-maternal donor) E4ORF1+ (pro-survival gene transduced) human umbilical vein endothelial cells (percutaneous injection formulation)
Number of severe injection site reactions
Severe refers to Grade ≥ 3 as per CTCAE v5.0 terms and grading
Time frame: Up to 180 days
Number of severe injection site reactions that are serious adverse events related to IP
Time frame: Up to 180 days
Proportion of treated responders
Treated responders defined as absence of the anal fissure with digital (e.g., index finger) palpation by investigator (supplemented by photo-documentation whenever possible) from baseline
Time frame: Up to 180 days
Changes in severity of pain on defecation (NRS) from (Day 0) baseline
Based on Numerical Rating Scale (NRS) measures at timepoints compared to baseline. Scale ranges from 0-10 with 0 representing no pain and severity of pain increasing chronologically.
Time frame: Days 0, 14, 21, 28, 42, 56, 90 and 180
Proportion of treated responders
Treated responders defined as absence of the anal fissure with digital (e.g., index finger) palpation by investigator (supplemented by photo-documentation whenever possible) from baseline (Day 0)
Time frame: Days 14, 21, 28, 42, 56, 90 and 180
Change in proportion of subjects
Subjects with ≥ 50% reduction in pain-on-defecation (NRS) from baseline (Day 0)
Time frame: Days 0, 14, 21, 28, 42, 56, 90 and 180
Proportion of treated subjects who have complete cessation of fissure-related symptoms
Time frame: Up to 180 days
Median percent change in fissure-wound from baseline (Day 0)
Median percent change in fissure wound size based on mm\^2 using digital photo-image analysis
Time frame: Days 0, 14, 21, 28, 42, 56, 90 and 180
Mean percent change in fissure-wound from baseline (Day 0)
Mean percent change in fissure wound size based on mm\^2 using digital photo-image analysis
Time frame: Days 0, 14, 21, 28, 42, 56, 90 and 180
Proportion of treated subjects who have ≥ 50% wound closure from baseline (Day 0)
Time frame: Day 14
Proportion of treated subjects who have ≥ 50% wound closure from baseline (Day 0)
Time frame: Day 21
Proportion of treated subjects who have ≥ 50% wound closure from baseline (Day 0)
Time frame: Day 28
Proportion of treated subjects who have ≥ 50% wound closure from baseline (Day 0)
Time frame: Day 42
Proportion of treated subjects who have ≥ 50% wound closure from baseline (Day 0)
Time frame: Day 56
Proportion of treated subjects who have ≥ 50% wound closure from baseline (Day 0)
Time frame: Day 90
Proportion of treated subjects who have ≥ 50% wound closure from baseline (Day 0)
Time frame: Day 180
Time-to-response in days in treated responders
Treated responders are defined as those with ≥50% reduction in pain on defecation (using numerical rating scale (NRS)) and ≥50% reduction in fissure-wound area from baseline (Day 0).
Time frame: Up to 180 days
Time-to symptom improvement in days in treated subjects who achieved symptom improvement
Symptom improvement is defined as a minimum 50% reduction in pain-on defecation (using numerical rating scale (NRS)) in treated subjects.
Time frame: Up to 180 days
Time-to 50% wound closure in days in subjects who achieved at least 50% wound closure
Time frame: Up to 180 days
Time-to complete wound closure in days in subjects who achieved complete wound closure
Time frame: Up to 80
Cumulative number of severe adverse events, defined and graded by NCI CTCAE v5.0
Time frame: Up to 180 days
Percent of serious adverse events, including relatedness category
Percent of SAE and relatedness categories of SAE as defined and graded by NCI CTCAE v5.0
Time frame: Up to 180 days
Percent of treatment-emergent adverse events per system organ class (SOC)
Time frame: Up to 180 days
Proportion of fissure relapse in treated subjects
Fissure relapse is defined as worsening of pain and increase in size after healing.
Time frame: Up to 180 days
Time-to-relapse in days in subjects who experienced relapse
Days to relapse from time of healing.
Time frame: Up to 180 days
Plan to share: No
No publications or documents are linked to this record.
Started Sep 2024 (actual). Primary completion is estimated for Dec 2026, 27 months after the start.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Weill Medical College of Cornell University →